Molecular Partners AG logo

MOLN - Molecular Partners AG Share Price

CHF17.38 0.2  1.1%

Last Trade - 4:30pm

Small Cap
Market Cap £327.4m
Enterprise Value £250.0m
Revenue £17.0m
Position in Universe 504th / 1040
Unlock MOLN Revenue
Relative Strength (%)
1m +16.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
26.6 29.1 23.0 20.0 10.4 20.4 64.3 59.0 -5.2%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Molecular Partners AG revenues increased 97% to SF20.4M. Net loss decreased 2% to SF36.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development Expense decrease of 46% to SF1.3M (expense), Interest income on loans and receivables increase from SF693K to SF1.6M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MOLN Revenue Unlock MOLN Revenue

Net Income

MOLN Net Income Unlock MOLN Revenue

Normalised EPS

MOLN Normalised EPS Unlock MOLN Revenue

PE Ratio Range

MOLN PE Ratio Range Unlock MOLN Revenue

Dividend Yield Range

MOLN Dividend Yield Range Unlock MOLN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MOLN EPS Forecasts Unlock MOLN Revenue
Profile Summary

Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated November 23, 2004
Public Since October 22, 2014
No. of Shareholders: n/a
No. of Employees: 135
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange SIX Swiss Exchange
Shares in Issue 22,764,072
Free Float (0.0%)
Eligible for
MOLN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MOLN
Upcoming Events for MOLN
Frequently Asked Questions for Molecular Partners AG
What is the Molecular Partners AG share price?

As of 4:30pm, shares in Molecular Partners AG are trading at CHF17.38, giving the company a market capitalisation of £327.4m. This share price information is delayed by 15 minutes.

How has the Molecular Partners AG share price performed this year?

Shares in Molecular Partners AG are currently trading at CHF17.38 and the price has moved by 32.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Molecular Partners AG price has moved by 37.66% over the past year.

What are the analyst and broker recommendations for Molecular Partners AG?

Of the analysts with advisory recommendations for Molecular Partners AG, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Molecular Partners AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Molecular Partners AG next release its financial results?

Molecular Partners AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Molecular Partners AG dividend yield?

Molecular Partners AG does not currently pay a dividend.

Does Molecular Partners AG pay a dividend?

Molecular Partners AG does not currently pay a dividend.

When does Molecular Partners AG next pay dividends?

Molecular Partners AG does not currently pay a dividend.

How do I buy Molecular Partners AG shares?

To buy shares in Molecular Partners AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Molecular Partners AG?

Shares in Molecular Partners AG are currently trading at CHF17.38, giving the company a market capitalisation of £327.4m.

Where are Molecular Partners AG shares listed? Where are Molecular Partners AG shares listed?

Here are the trading details for Molecular Partners AG:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: MOLN
What kind of share is Molecular Partners AG?

Based on an overall assessment of its quality, value and momentum, Molecular Partners AG is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Molecular Partners AG share price forecast 2020?

Shares in Molecular Partners AG are currently priced at CHF17.38. At that level they are trading at 44.19% discount to the analyst consensus target price of 0.00.

Analysts covering Molecular Partners AG currently have a consensus Earnings Per Share (EPS) forecast of -0.125 for the next financial year.

How can I tell whether the Molecular Partners AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Molecular Partners AG. Over the past six months, the relative strength of its shares against the market has been -5.92%. At the current price of CHF17.38, shares in Molecular Partners AG are trading at -10.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Molecular Partners AG PE Ratio?

We were not able to find PE ratio data for Molecular Partners AG.

Who are the key directors of Molecular Partners AG?

Molecular Partners AG's management team is headed by:

Andreas Emmenegger - CFO
Michael Stumpp - COO
Patrick Amstutz - CMG
William Lee - NED
Goran Ando - NVC
Andreas Harstrick - MGB
Steven Holtzman - NED
Gwendolyn Fyfe - NED
William Burns - NEC
Pamela Trail - CSO
Nicolas Leupin - MGB
Who are the major shareholders of Molecular Partners AG?

Here are the top five shareholders of Molecular Partners AG based on the size of their shareholding:

Index Ventures SA Venture Capital
Percentage owned: 7.86% (1.71m shares)
Wyss (Hansjoerg) Individual Investor
Percentage owned: 7.47% (2.04m shares)
Suvretta Capital Management, LLC Hedge Fund
Percentage owned: 6.4% (1.75m shares)
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund
Percentage owned: 6.13% (1.68m shares)
Essex Woodlands Management, Inc. Venture Capital
Percentage owned: 5.93% (1.62m shares)
Similar to MOLN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.